F
Feng Shen
Researcher at Second Military Medical University
Publications - 403
Citations - 12498
Feng Shen is an academic researcher from Second Military Medical University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 46, co-authored 313 publications receiving 8315 citations.
Papers
More filters
Journal ArticleDOI
A novel online calculator to predict perioperative blood transfusion in patients undergoing liver resection for hepatocellular carcinoma: an international multicenter study.
Bing Quan,Wan-Guang Zhang,Matteo Serenari,Lei Liang,Hao Xing,Chao Li,Ming-Da Wang,Wan Yee Lau,Myron Schwartz,Timothy M. Pawlik,Matteo Cescon,Meng-Chao Wu,Feng Shen,Tian Yang +13 more
TL;DR: A nomogram model, using an easy-to-access website, can be used to calculate the PBT risk and identify which patients undergoing HCC resection are at high risks of PBT and can benefit most by using blood conservation techniques.
Journal ArticleDOI
Radiomics-Based Preoperative Prediction of Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma Using Contrast-Enhanced Computed Tomography
Shuaitong Zhang,Sheng-yu Huang,Wei-Hua He,Jingwei Wei,Lei Huo,Ningyang Jia,Jianbo Lin,Zhenchao Tang,Yunfei Yuan,Jie Tian,Feng Shen,Jun Li +11 more
TL;DR: Investigation of the role of radiomics-based method in predicting LN metastasis for patients with intrahepatic cholangiocarcinoma found its performance was determined by discrimination, calibration, and stratification of long-term prognosis.
Journal ArticleDOI
Prognostic factors of resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis of high-quality studies:
Lei Liang,Chao Li,Hang-Dong Jia,Yong-Kang Diao,Hao Xing,Timothy M. Pawlik,Wan Yee Lau,Feng Shen,Dong-Sheng Huang,Cheng-Wu Zhang,Tian Yang +10 more
TL;DR: In this paper, the authors defined and characterized current available evidence on prognostic factors as follows: prognostic factor associated with outcome following resection of perihilar cholangiocarcinoma.
Journal ArticleDOI
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wenming Cong,Mengsu Zeng,Weiping Zhou,Ping Bie,Lianxin Liu,Tian-Fu Wen,Ming Kuang,Guohong Han,Zhiping Yan,Ruibao Liu,Ligong Lu,Zhenggang Ren,Zhaochong Zeng,Ping Liang,C. H. Lin,Min Chen,Fuhua Yan,Wenping Wang,Jin-Xiu Hou,Yuan Ji,Jingping Yun,Xueli Bai,Dingfang Cai,Weixia Chen,Yongjun Chen,Wenwu Cheng,Shuqun Cheng,Chaoliu Dai,Wen-Tao Guo,Yabing Guo,Baojin Hua,Xiao-Wu Huang,Weidong Jia,Qiu Li,Tao Li,Xun Li,Yaming Li,Yexiong Li,Jun Liang,Changquan Ling,Tian Liu,Xiu-Feng Liu,Shichun Lu,Guoyue Lv,Yilei Mao,Zhiqiang Meng,Tao Peng,Weixin Ren,Hongcheng Shi,Guoming Shi,Ming Quan Shi,Tianqiang Song,Kaishan Tao,Jianhua Wang,Kui Wang,Lu Wang,Wentao Wang,Xiaoying Wang,Zhiming Wang,Bo Xiang,B. Xing,Jianming Xu,Jiamei Yang,Jianyong Yang,Yefa Yang,Yunke Yang,Shenglong Ye,Zhenyu Yin,Yong Zeng,Bixiang Zhang,Bo-Heng Zhang,Leida Zhang,Shuijun Zhang,Ti Zhang,Yanqiao Zhang,Min Zhao,Yongfu Zhao,Honggang Zheng,Ledu Zhou,Jiye Zhu,Kangshun Zhu,Rong Liu,Ying-Hong Shi,Yongsheng Xiao,Lan Zhang,Chun Yang,Zhifeng Wu,Zhi Dai,Minshan Chen,Jianqiang Cai,Weilin Wang,Xiujun Cai,Qiang Li,Feng Shen,Shukui Qin,Gao-Jun Teng,Jiahong Dong,Jiali Fan +100 more
TL;DR: Wang et al. as discussed by the authors proposed a new guideline for primary liver cancer in China, which aims to encourage the implementation of evidence-based practice, and improve the national average five-year survival rate for patients with liver cancer.
Journal ArticleDOI
Association between HBV Pre-S mutations and the intracellular HBV DNAs in HBsAg-positive hepatocellular carcinoma in China.
Hui Wang,Aihua Wang,Olav A. Gressner,Meng Fang,Xing Gu,Qiang Ji,Shu-Qun Cheng,Feng Shen,Chunfang Gao +8 more
TL;DR: This study aimed to determine the clinical features and the contribution of HBV mutations to postoperative prognosis for hepatocellular carcinoma patients with HBsAg (+) in China and to disclose the virological features to implement a more clinically personalized therapy and to improve the prognosis of HCC patients.